Microchip Biotechnologies Inc.
This article was originally published in Start Up
Executive Summary
Even as next-generation sequencing technologies make their way to the market, improving the efficiency of sample prep at the front end of large-scale genome sequencing will continue to be a viable strategy for significantly driving down costs and in so doing, expand applications. That's the initial strategy of Microchip Biotechnologies, which is commercializing microfluidic technology originally developed in the lab of Richard Mathies at Berkeley.
You may also be interested in...
Next-generation Sequencing: Slowly Moving towards the $1,000 Genome
Even if most attempts to read DNA strands in real time appear stalled and the goal of true single-molecule sequencing has, with the notable exception of Helicos, for the most part given way (at least for the time being) in favor of cluster-based approaches with lower data densities, there's still plenty of opportunity for start-ups to advance the field of next-generation sequencing: with microfluidics, nanotechnology, and biochemistries to better enable direct DNA observation and analysis.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.